ALMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Alumis Inc (ALMS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support, positive clinical trial results, insider buying trends, and a favorable long-term growth outlook. Despite some short-term financial challenges, the company's lead asset, envudeucitinib, has blockbuster potential in the TYK2 inhibitor space, making it a compelling investment opportunity.
The technical indicators show a mixed picture. The MACD histogram is negative and contracting, suggesting a weak momentum. However, the RSI is neutral at 59.235, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot level of 26.084, with resistance at 27.431 and support at 24.736. Overall, the technicals lean slightly bullish.
Strong Phase III clinical trial results for envudeucitinib in moderate-to-severe plaque psoriasis.
Analysts have raised price targets significantly, with targets ranging from $32 to $50, citing reduced approval risk and a higher revenue ceiling.
Insider buying has increased by 586.17% over the last month, signaling confidence from company insiders.
Alumis' lead asset has the potential to be a best-in-class TYK2 inhibitor, with multibillion-dollar market opportunities.
Financial performance shows a net loss of -$110.75M in Q3 2025, although it improved by 18.94% YoY.
EPS dropped by -38.01% YoY, reflecting ongoing financial challenges.
No recent congress trading data or significant hedge fund activity, which could indicate limited institutional interest.
In Q3 2025, revenue remained flat at $2.066M YoY, while net income improved by 18.94% YoY to -$110.75M. EPS dropped by -38.01% YoY to -1.06, reflecting financial challenges. Gross margin remained stable at 100%. Overall, the company is still in a growth phase, with significant R&D investment in its clinical pipeline.
Analysts are overwhelmingly bullish on ALMS, with multiple firms raising price targets significantly after the positive Phase III trial results. The price targets range from $32 to $50, with a consensus Buy rating. Analysts highlight the reduced approval risk, competitive data for envudeucitinib, and its potential to dominate the TYK2 inhibitor market.
